Literature DB >> 23911242

Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals.

Karen Meyvis1, An Verrijken, Kristien Wouters, Luc Van Gaal.   

Abstract

OBJECTIVE: To explore the relationship between adiponectin and albuminuria in a large group of overweight and obese nondiabetic individuals after controlling for potential confounders.
MATERIAL AND METHODS: Detailed anthropometry, computed tomography-measured visceral abdominal adipose tissue, 24-h albuminuria, adiponectin and a series of biochemical parameters were assessed. Four hundred forty patients, predominantly of Caucasian origin, were included (80.2% female). A multiple linear regression model was developed, with albuminuria as the dependent variable and potential predictors as independent variables.
RESULTS: The mean age was 40±13 years, the mean body mass index was 35.7±6.6 kg/m2, and the median visceral abdominal adipose tissue was 142.4 (92.3-194.0) cm2. 10.9% of subjects exhibited microalbuminuria. The median adiponectin level was 9.08 (6.23-12.94) μg/ml, and the median fasting serum glucose level was 83 (77-89) mg/dl. The strongest significant univariate correlations with albuminuria were visceral abdominal adipose tissue (r=0.258, p<0.001), adiponectin (r=-0.265, p<0.001), waist circumference (r=0.250, p<0.001), waist-to-hip ratio (r=0.236, p<0.001) and high-density lipoprotein cholesterol (r=-0.211, p<0.001). The multiple linear regression model revealed a significant positive independent correlation between visceral abdominal adipose tissue and albuminuria (r=0.134, p=0.033), between fasting glucose levels and albuminuria (r=0.390, p=0.029) and between gender and albuminuria (r=0.107, p=0.038). A significant independent negative correlation was identified between adiponectin and albuminuria (r=-0.255, p=0.022).
CONCLUSIONS: We observed an independent inverse relationship between adiponectin and albuminuria in overweight and obese nondiabetic individuals. Further investigations are needed to confirm this finding and to clarify whether adiponectin is a risk marker or plays a causative role in developing obesity-induced nephropathy.
© 2013.

Entities:  

Keywords:  5' adenosine monophosphate-activated protein kinase; AMPK; Adipokines; BMI; HDL-C; LDL-C; MDRD; Microalbuminuria; Modification of Diet in Renal Disease; Obesity; SAT; VAT; Visceral abdominal adipose tissue; WHR; body mass index; eGFR; estimated glomerular filtration rate; high sensitive-C-reactive protein; high-density lipoprotein cholesterol; hs-CRP; low-density lipoprotein cholesterol; subcutaneous abdominal adipose tissue; visceral abdominal adipose tissue; waist-to-hip ratio

Mesh:

Substances:

Year:  2013        PMID: 23911242     DOI: 10.1016/j.metabol.2013.05.023

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

Review 1.  Podocytes, signaling pathways, and vascular factors in diabetic kidney disease.

Authors:  Frank C Brosius; Richard J Coward
Journal:  Adv Chronic Kidney Dis       Date:  2014-05       Impact factor: 3.620

2.  Interaction of thrombospondin1 and CD36 contributes to obesity-associated podocytopathy.

Authors:  Wenpeng Cui; Hasiyeti Maimaitiyiming; Qi Zhou; Heather Norman; Changcheng Zhou; Shuxia Wang
Journal:  Biochim Biophys Acta       Date:  2015-03-31

Review 3.  Obesity, oxidative stress, and fibrosis in chronic kidney disease.

Authors:  Kumar Sharma
Journal:  Kidney Int Suppl (2011)       Date:  2014-11

4.  Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia.

Authors:  Allon Wagner; Noa Cohen; Thomas Kelder; Uri Amit; Elad Liebman; David M Steinberg; Marijana Radonjic; Eytan Ruppin
Journal:  Mol Syst Biol       Date:  2015-03       Impact factor: 11.429

5.  Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb
Journal:  J Basic Clin Pharm       Date:  2016-12

6.  Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort.

Authors:  Kieren J Mather; Qing Pan; William C Knowler; Tohru Funahashi; George A Bray; Richard Arakaki; Bonita Falkner; Kumar Sharma; Barry J Goldstein
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.